6th Feb 2024 10:08
(Sharecast News) - Consumer healthcare company Futura said on Tuesday that 2023 had been a "transformational year", with the group generating its first meaningful revenues and laying the foundations for "significant growth acceleration".
Read more15th Jan 2024 14:59
(Sharecast News) - Sexual health product developer Futura Medical announced an extension of its exclusive licensing agreement with Cooper Consumer Health on Monday.
Read more2nd Oct 2023 14:22
(Sharecast News) - Sexual health specialist Futura Medical announced the successful acquisition of an EU patent for its MED3000 topical erectile dysfunction product on Monday.
Read more17th Jul 2023 08:33
(Sharecast News) - Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
Read more18th Apr 2023 13:09
(Sharecast News) - Sexual health-focussed pharmaceutical company Futura Medical announced on Tuesday that its topical gel formulation for the treatment of erectile dysfunction (ED), MED3000, is now available in the UK under the 'Eroxon' brand.
Read more13th Dec 2022 12:51
(Sharecast News) - Drug delivery technology developer Futura Medical updated the market on the regulatory progress and recent commercial activities for its 'MED3000' topical gel treatment for erectile dysfunction (ED).
Read more3rd Oct 2022 13:13
(Sharecast News) - Futura Medical has completed the work required for the FDA to grant marketing authorisation for 'MED3000', its fast acting clinically proven treatment for erectile dysfunction, it announced on Monday.
Read more23rd Mar 2022 15:35
(Sharecast News) - Pharmaceutical and drug delivery technology developer Futura Medical has entered into a licensing agreement with Menarini Korea, it announced on Wednesday, for the exclusive rights to commercialise the company's topical gel-based erectile dysfunction treatment MED3000 in South Korea.
Read more20th Dec 2021 10:46
(Sharecast News) - Futura Medical updated the market on regulatory and commercial progress for 'MED3000', its topical gel formulation for the treatment of erectile dysfunction, on Monday.
Read more27th Sep 2021 16:54
(Sharecast News) - Transdermal drug delivery technology company Futura Medical has entered into a licensing agreement with Labatec Pharma, a Switzerland-based specialty pharma company focussed on commercialisation in the Europe and Middle East and North Africa (MENA) regions, it announced on Monday.
Read more31st Aug 2021 15:08
(Sharecast News) - Futura Medical has entered into a licensing agreement with M8 Pharmaceuticals, a specialty biopharmaceutical company focused on commercialisation in Latin America, for the rights to exclusively develop and commercialise its topical, gel-based erectile dysfunction (ED) treatment MED3000 in Brazil and Mexico, it announced on Tuesday.
Read more28th Jun 2021 10:02
(Sharecast News) - Pharmaceutical company Futura Medical updated the market on its topical erectile dysfunction (ED) treatment 'MED3000' on Monday, given it now had CE-mark approval in Europe for the treatment of ED in adult men.
Read more3rd Jun 2021 12:50
(Sharecast News) - Experian: RBC Capital Markets downgrades to underperform with a target price of 2,400p.
Read more30th Apr 2021 13:23
(Sharecast News) - Pharmaceutical company Futura Medical has received CE marking for its 'MED3000' erectile dysfunction gel, it announced on Friday.
Read more22nd Mar 2021 08:12
(Sharecast News) - Futura Medical shares surged on Monday after the company said it had agreed with the US Food and Drug Administration on the protocol for a small confirmatory clinical study of its erectile dysfunction gel, MED3000.
Read more